Investigational New Drug Applications; Technical Amendment

Text

---

 

Federal Register: October 29, 2009 (Volume 74, Number 208)

Rules and Regulations

Page 55770-55771

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr29oc09-10

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration 21 CFR Part 312

Docket No. FDA-2009-N-0464

Investigational New Drug Applications; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending its investigational new drug application (IND) regulations to add an address for applicants to submit INDs for in vivo bioavailability and bioequivalence studies in humans. INDs for these studies that are intended to support abbreviated new drug applications (ANDAs) should be sent directly to the

Page 55771

Office of Generic Drugs. This action is being taken to ensure accuracy and clarity in the agency's regulations.

DATES: This rule is effective October 29, 2009.

FOR FURTHER INFORMATION CONTACT: Peter Chen, Center for Drug Evaluation and Research (HFD-615), Food and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 240-276-8436.

SUPPLEMENTARY INFORMATION: FDA is amending its regulations in part 312

(21 CFR part 312) to clarify where ANDA applicants should submit INDs for in vivo bioavailability and bioequivalence studies in humans. This document adds the address for the Office of Generic Drugs in Sec. 312.140(a)(1).

Publication of this document constitutes final action on these changes under the Administrative Procedure Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to add an address for the submission of INDs related to ANDAs.

List of Subjects in 21 CFR Part 312

Drugs, Exports, Imports, Investigations, Labeling, Medical research, Reporting and recordkeeping requirements, Safety. 0

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 312 is amended as follows:

PART 312--INVESTIGATIONAL NEW DRUG APPLICATION 0 1. The authority citation for 21 CFR part 312 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360bbb, 371; 42 U.S.C. 262. 0 2. Section 312.140 is amended by revising paragraph (a)(1) to read as follows:

Sec. 312.140 Address for correspondence.

(a) * * *

(1) For drug products regulated by CDER. Send the IND submission to the Central Document Room, Center for Drug Evaluation and Research,

Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266; except send an IND submission for an in vivo bioavailability or bioequivalence study in humans to support an abbreviated new drug application to the Office of Generic Drugs (HFD- 600), Center for Drug Evaluation and Research, Food and Drug

Administration, Metro Park North II, 7500 Standish Pl., Rockville, MD 20855.

* * * * *

Dated: October 23, 2009.

David Horowitz,

Assistant Commissioner for Policy.

FR Doc. E9-26095 Filed 10-28-09; 8:45 am

BILLING CODE 4160-01-S

---